恶性淋巴瘤骨髓受累:定量PET与MRI生物标志物的评估
本研究纳入60例初治淋巴瘤患者,评估[18F]-FDG-PET/CT的SUVmax-ratio与全身DWI的ADCmean对局灶性和弥漫性骨髓受累的诊断价值。结果显示SUVmax-ratio对局灶性骨髓受累的敏感度/特异度为87.5%/86.4%,对弥漫性为100%/43.2%;ADCmean对局灶性为100%/90.9%,对弥漫性为87.5%/56.8%。结论认为以肝脏为参考组织的定量PET/CT可能有助于区分骨髓受累与正常骨髓,但弥漫性受累特异度较低;定量DWI仅可用于区分局灶性骨髓病变与正常骨髓。
要点
- SUVmax-ratio诊断弥漫性骨髓受累敏感度100%但特异度仅43.2%,需谨慎解读。
- ADCmean诊断局灶性骨髓受累敏感度100%、特异度90.9%,对弥漫性特异度56.8%。
- SUVmax-ratio与ADCmean在不同组间均无显著相关性。
核心结论
- 以肝脏为参考组织的定量[18F]-FDG-PET/CT可能有助于区分淋巴瘤患者的骨髓受累与正常骨髓,尽管对弥漫性骨髓受累的特异度相当低;定量DWI仅可用于区分局灶性骨髓病变与正常骨髓。
研究设计与样本
- 经机构审查委员会批准的回顾性研究,纳入60例组织学证实的初治淋巴瘤患者(28例男性,平均年龄51.2±16.7岁),均在7天内接受[18F]-FDG-PET/CT和全身DWI检查,并接受常规骨髓活检。
关键影像表现/征象
- 骨髓受累见于60例中的16例,其中8例为弥漫性浸润。
- SUVmax-ratio和ADCmean从局灶性病变提取,无局灶性病变时从胸椎(Th8)、腰椎(L4)、骶骨(S1)和髂嵴提取。
诊断标准与关键数值
- SUVmax-ratio诊断局灶性骨髓受累的截断值为95.25%,敏感度/特异度为87.5%/86.4%。
- SUVmax-ratio诊断弥漫性骨髓受累的截断值为70.2%,敏感度/特异度为100%/43.2%。
- ADCmean诊断局灶性骨髓受累的截断值为0.498,敏感度/特异度为100%/90.9%。
- ADCmean诊断弥漫性骨髓受累的截断值为0.401,敏感度/特异度为87.5%/56.8%。
临床应用与阅片要点
- 以肝脏为参考组织计算SUVmax-ratio,可用于辅助区分淋巴瘤患者的骨髓受累与正常骨髓。
- 定量DWI的ADCmean仅可用于区分局灶性骨髓病变与正常骨髓,不适用于弥漫性骨髓受累的鉴别。
- SUVmax-ratio诊断弥漫性骨髓受累时特异度仅43.2%,解读阳性结果时需注意其局限性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: This study aimed to determine the diagnostic utility of standardized uptake values (SUV) and apparent diffusion coefficients (ADC) for assessment of focal and diffuse bone marrow involvement in patients with malignant lymphoma.
MATERIALS AND METHODS: Sixty treatment-naive patients (28 males; mean age 51.2 ± 16.7 years) with histologically proven lymphoma, who underwent fludeoxyglucose (18F) positron emission tomography-computed tomography ([F18]-FDG-PET/CT) and whole-body diffusion-weighted imaging (WB-DWI) within 7 days, and also routine bone marrow biopsy, were included in this institutional review board-approved, retrospective study. The maximum SUV (SUVmax) on [F18]-FDG-PET/CT, and the mean ADC (ADCmean, ×10-3 mm2/s) on whole-body-DWI, were extracted from focal lesions, or, in their absence, from the thoracic (Th8) and lumbar vertebral bodies (L4), the sacral bone (S1), and the iliac crest. Lesion-to-liver-ratios (SUVmax-ratio) were calculated. Pearson correlation coefficients were used to assess the correlation between SUVmax-ratios and ADCmean values.
RESULTS: Bone marrow involvement was observed in 16 of 60 patients (8 of 16 with diffuse infiltration). The SUVmax-ratio cutoff value was 95.25% for focal and 70.2% for diffuse bone marrow involvement (sensitivity/specificity of 87.5%/86.4% and 100%/43.2%, respectively). The ADCmean cutoff value was 0.498 for focal and 0.401 for diffuse bone marrow involvement (sensitivity/specificity of 100%/90.9% and 87.5%/56.8%, respectively). No significant correlations were found between SUVmax-ratios and ADCmean values in the different groups.
CONCLUSION: With the liver as reference tissue, quantitative [F18]-FDG-PET/CT may be useful to differentiate bone marrow involvement from normal bone marrow in patients with lymphoma, even though the specificity for diffuse marrow involvement is rather low. Quantitative DWI can be used only to distinguish focal bone marrow lesions from normal bone marrow.
引用
- Asenbaum U, Nolz R, Karanikas G, et al. Bone Marrow Involvement in Malignant Lymphoma: Evaluation of Quantitative PET and MRI Biomarkers. Acad Radiol. 2017. PMID: 29199055. doi:10.1016/j.acra.2017.10.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。